This article needs additional citations for
verification. (June 2020) |
Identifiers | |
---|---|
| |
Chemical and physical data | |
Formula | C13H18N2O4 |
Molar mass | 266.13 g/mol (freebase) 239.78 g/mol (hydrochloride) g·mol−1 |
3D model ( JSmol) | |
| |
|
M-alpha-HMCA (3-(benzo[d][1,3]dioxol-5-yl)-2-hydroxy-N,2-dimethyl-3-(methylamino)propanamide) is an unintentional sideproduct during the synthesis of MDMA using PMK glycidate as a precursor. It was identified in MDMA pills. [1] The biological properties of this molecule have not yet been documented. The backbone of the chemical structure is M-alpha whose psychoactive activity has been described by Alexander Shulgin.[ citation needed]
This article needs additional citations for
verification. (June 2020) |
Identifiers | |
---|---|
| |
Chemical and physical data | |
Formula | C13H18N2O4 |
Molar mass | 266.13 g/mol (freebase) 239.78 g/mol (hydrochloride) g·mol−1 |
3D model ( JSmol) | |
| |
|
M-alpha-HMCA (3-(benzo[d][1,3]dioxol-5-yl)-2-hydroxy-N,2-dimethyl-3-(methylamino)propanamide) is an unintentional sideproduct during the synthesis of MDMA using PMK glycidate as a precursor. It was identified in MDMA pills. [1] The biological properties of this molecule have not yet been documented. The backbone of the chemical structure is M-alpha whose psychoactive activity has been described by Alexander Shulgin.[ citation needed]